Howard Capital Management Inc. Has $1.72 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Howard Capital Management Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.7% in the first quarter, Holdings Channel reports. The institutional investor owned 2,709 shares of the biopharmaceutical company’s stock after selling 393 shares during the period. Howard Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,718,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Brighton Jones LLC raised its holdings in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after acquiring an additional 686 shares in the last quarter. American Assets Inc. acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $427,000. Clearbridge Investments LLC raised its stake in shares of Regeneron Pharmaceuticals by 0.7% in the 4th quarter. Clearbridge Investments LLC now owns 3,978 shares of the biopharmaceutical company’s stock valued at $2,834,000 after buying an additional 26 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock valued at $1,726,940,000 after acquiring an additional 155,369 shares in the last quarter. Finally, Kesler Norman & Wride LLC bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at about $316,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ REGN opened at $554.58 on Thursday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The firm has a market capitalization of $59.87 billion, a P/E ratio of 14.12, a P/E/G ratio of 2.09 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The company’s 50 day simple moving average is $539.67 and its 200 day simple moving average is $606.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter in the previous year, the firm posted $9.55 EPS. The business’s revenue was down 3.7% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.63%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 8.96%.

Analyst Ratings Changes

REGN has been the subject of several analyst reports. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $755.00 to $754.00 and set an “overweight” rating for the company in a research report on Thursday, July 10th. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 1st. Argus lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 30th. The Goldman Sachs Group reduced their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating on the stock in a report on Wednesday, April 30th. Finally, Royal Bank Of Canada cut Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 price target for the company. in a report on Friday, May 30th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $837.61.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.